Back to Screener

Healthcare

Arjo AB (publ)(ARRJF)

Live Price

Offline

$2.50

+0.00% today

1Y Change

-18.24%

Window

Jun 27, 2025 โ†’ Jun 18, 2026

Market Cap
$6.72B
Revenue Growth
-2.6%
EPS Growth
-33.3%
Dividend Yield
3.8%

Coverage: 251 bars ยท Jun 27, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Arjo AB (publ) (ARRJF) is a Healthcare stock with a market cap of $6.72B. The stock last traded around $2.50 and down 18.2% across the available one-year price window (Jun 27, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of -2.6%, EPS growth of -33.3%, a dividend yield of 3.8%. What stands out right now is revenue -2.6%, EPS -33.3%, free cash flow -32.8% with operating margin 7.2% and ROIC 3.8%. The dividend matters to the case here, with a current yield around 3.8%. Valuation is more restrained than many high-expectation growth names at P/E 19.2 and price/sales 0.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines ARRJF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

ARRJF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

ARRJF

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

ARRJF Max Drawdown

-28.29%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for ARRJF and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for ARRJF

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.